Relapsed Acute Myeloid Leukemia Clinical Trial
Official title:
Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia
Background: Acute myeloid leukemia (AML) is a cancer of the white blood cells. It is fatal if not treated. Treatment for AML that has not responded to treatment (refractory) or has returned after treatment (relapsed) often do not work. Researchers want to see if an immunotherapy drug, combined with a less intense chemotherapy, may be able to help. Objective: To test if pembrolizumab, in combination with decitabine, is a possible treatment for people with relapsed or refractory AML. Eligibility: Adults 18 years of age and older with refractory AML or relapsed AML. Design: Participants will be first screened for eligibility. The study is counted in 21-day cycles. The initial phase of the study consists of 8 cycles. Participants may be in the study for up to 2 years if they are responding to the treatment. The first 3 weeks of treatment is usually done in the hospital. The rest may be done as an outpatient. Participants will get pembrolizumab at the beginning of each cycle through an IV. Participants will usually get decitabine by IV on days 8 12 and days 15 19 of every other cycle. Participants will give blood samples. Participants will have bone marrow exams. A needle will be inserted into the hip to extract cells from the bone marrow. Some participants may give a sample of saliva from the inside of their cheek. Some participants may give a small skin sample. The top layer of the skin is removed. Some patients may require leukapheresis before starting treatment. This is a procedure to remove leukemia cells in the blood stream.
This is a pilot study to determine the feasibility of a novel combination of Pembrolizumab and Decitabine in relapsed/refractory adult AML patients. While both Pembrolizumab and Decitabine are FDA approved agents, this study will explore giving these drugs in combination for this population of patients. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01961765 -
Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia
|
Phase 1 | |
| Recruiting |
NCT04582864 -
Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)
|
Phase 2 | |
| Not yet recruiting |
NCT05362942 -
Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy for Acute Myeloid Leukemia
|
Phase 2 | |
| Terminated |
NCT02109627 -
Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML
|
Phase 1 | |
| Withdrawn |
NCT04354025 -
Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or Relapsed AML
|
Phase 2 | |
| Withdrawn |
NCT04893915 -
Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS
|
Phase 2 | |
| Recruiting |
NCT04891757 -
FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies
|
Phase 1 | |
| Suspended |
NCT04797767 -
Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
|
Phase 1 | |
| Completed |
NCT05456048 -
Influence of Molecular Abnormalities on Response of VAH vs. VEN+HMA in RR-AML
|
||
| Terminated |
NCT05028751 -
A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06017258 -
A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia
|
Phase 1 | |
| Recruiting |
NCT06177067 -
Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
|
Phase 1 |